

# European Journal of Immunology

Supplement S1



European Federation of  
Immunological Societies

**VIRTUAL  
BOCI 2021**

September 1-4, 2021  
Pre-Congress Meetings August 31, 2021

**Abstract Book**

*Opening Doors to the  
World of Immunology*

[www.eci2021.org](http://www.eci2021.org)

The Turkish Society of Immunology [www.turkimmunoloji.org](http://www.turkimmunoloji.org)  
and The Immunological Society of Serbia [www.isos.rs](http://www.isos.rs)



[/ECI2021](https://www.facebook.com/ECI2021) [@2021ECI](https://twitter.com/@2021ECI) [@eci\\_2021](https://www.instagram.com/@eci_2021)  
[/company/61th-european-congress-of-immunology/](https://www.linkedin.com/company/61th-european-congress-of-immunology/)

[www.eji-journal.eu](http://www.eji-journal.eu)

WILEY

# Abstracts of ECI 2021

## 6<sup>th</sup> European Congress of Immunology

1-4 September 2021  
Virtual meeting

*European Journal of Immunology* Volume 51, Suppl. 1, August 2021

This abstract book can be searched using the PDF search function to look, for example, for the Abstract number if applicable or author name.

To cite an Abstract, please use the following format:

Abstract title. Authors. Conference: 6<sup>th</sup> European Congress of Immunology. Abstracts. Location Virtual. Date September 1-4, 2021. Eur. J. Immunol. 2021. 51, S1, page number(s). Meeting Abstract number [the Abstract number if applicable can be found above the title]

**Disclaimer:**

This abstract book has been produced using author-supplied copy and in the format provided by the conference organizer.

No responsibility is assumed for any claims, instructions, methods or drug dosages contained in the abstracts; it is recommended that these are verified independently.

*This Abstract book was corrected after online publication on 25 August 2021 by including two Abstracts that were missing from the initial supplied copy*

## ABSTRACT REVIEWERS

The organizers of the 6<sup>th</sup> European Congress of Immunology would like to extend their special thanks to all abstract reviewers for their contribution and time they dedicated to the success of the congress:

Adriana Narcisa Munteanu	Romania	James Brewer	United Kingdom
Ahmet Eken	Turkey	Jelena Djokic	Serbia
Akif Turna	Turkey	Jordi Cano Orchoando	Spain
Aleksandra Popov Aleksandrov	Serbia	Jürgen Wittmann	Germany
Alexandra Siorenta	Greece	Katerina Tarassi	Greece
Alexandra Tsirogiani	Greece	Kingston Mills	Ireland
Alisa Gruden-Movsesijan	Serbia	Krassimira Todorova	Bulgaria
Amiram Ariel	Israel	Krisztina Buzas	Hungary
Andreas Radbruch	Germany	Lazar Popović	Serbia
Anita Milicic	United Kingdom	Luis Graça	Portugal
Anna Sediva	Czech Republic	Luke Foster	United Kingdom
Anne Caignard	France	Marcela Vlkova	Czech Republic
Arpad Lanyi	Hungary	Marco A. Cassatella	Italy
Arzu L. Aral	Turkey	Marcos Lopez-Hoyos	Spain
Aslı Gelincik Akkor	Turkey	Marieke Van Ham	The Netherlands
Aude Magerus	France	Marinela Bostan	Romania
Ayça Sayı Yazgan	Turkey	Marta Szell	Hungary
Ayça Kiyıkım	Turkey	Martin Schwarzer	Czech Republic
Ayşegül Atak Yücel	Turkey	Martina Colicchia	United Kingdom
Batu Erman	Turkey	Maxim Nosenko	Russia
Biljana Božić Nedeljković	Serbia	Mayda Gürsel	Turkey
Bojan Polić	Croatia	Michael Lohoff	Germany
Carsten Watzl	Germany	Mira Barda-Saad	Israel
Ceren Çıracı	Turkey	Micha Berger	Israel
Cezmi Akdiş	Switzerland	Milada Sirova	Czech Republic
Danka Grcevic	Croatia	Mirjam Heemskerck	The Netherlands
Delphine Sauce	France	Mirjana Nacka-Aleksić	Serbia
Dicle Güç	Turkey	Muhlis Cem Ar	Turkey
Diana Dudziak	Germany	Nada Pejnovic	Serbia
Diğdem Yöyen Ermiş	Turkey	Nataša Ilić	Serbia
Djordje Miljkovic	Serbia	Nemanja Jovicic	Serbia
Dominik Filipp	Czech Republic	Noushine Mossadegh-Keller	France
Duygu Sağ	Turkey	Peter Heeringa	The Netherlands
Ed Lavelle	Ireland	Sergej Tomić	Serbia
Edit Buzas	Hungary	Serkan Belkaya	Turkey
Elif Karakoç Aydınar	Turkey	Silke Appel	Norway
Erika Jensen-Jarolim	Austria	Slavko Mojsilovic	Serbia
Eva Martinez Caceres	Spain	Soren Hayrabedian	Bulgaria
Eva Untersmayr	Austria	Srdja Janković	Serbia
Gerhard Wingender	Turkey	Sylvia Knapp	Austria
Goran Marjanović	Serbia	Şefik Alkan	Turkey
Güher Saruhan Direskeneli	Turkey	Tal Shay	Israel
Günnur Deniz	Turkey	Tamara Saksida	Serbia
Güneş Esendağlı	Turkey	Tanja Džopalić	Serbia
Haluk Barbaros Oral	Turkey	Tolga Sütülü	Turkey
Haner Direskeneli	Turkey	Trevor Owens	Denmark
Hanna Jarva	Finland	Uğur Sezerman	Turkey
Hannes Stockinger	Austria	Wilfried Ellmeier	Austria
İhsan Gürsel	Turkey	Yıldız Camcıoğlu	Turkey
Iva Hafner Bratkovic	Slovenia	Zimmer Jacques	Luxembourg
Ivan Pilipović	Serbia	Zoltán Prohászka	Hungary
Ivana Stojanovic	Serbia	Zsolt Komlosi	Hungary
Ivanka Tsacheva	Bulgaria		
Jacques Nunes	France		

## POSTER PRESENTATIONS

## P-0808

**Germline STAT3-activating mutations from autoimmunity and lymphoid malignancy perturb mouse and human T lymphocytes**

**Etienne Masle Farquhar**, Timothy Peters, Ghamdan Al Eryani, Kathryn Payne, Geetha Rao, Mandeep Singh, Katherine Jackson, Robert Brink, Stuart Tangye, Joanne Reed, Christopher Goodnow

*Immunology Division, Garvan Institute of Medical Research, Sydney, Australia*

Signal transducer and activator of transcription 3 (STAT3) is a latent transcription factor with pleiotropic roles in hematopoietic and non-hematopoietic cells, that regulates gene expression downstream of cell surface cytokine and hormone receptors. Heterozygous germline loss-of-function *STAT3* mutations lead to the primary immunodeficiency hyper-IgE syndrome (HIES) while somatic gain-of-function *STAT3* mutations recur in human solid organ malignancies and non-Hodgkin lymphoma. Recently, germline heterozygous gain-of-function mutations in *STAT3* were shown to result in early-onset and multi-organ autoimmunity with aspects of immunodeficiency. Affected individuals share characteristics with autoimmune lymphoproliferative syndrome (ALPS) and immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome, including reduced T regulatory cell numbers and suppressive activity. They present with variable early-onset autoimmune symptoms including type 1 diabetes, juvenile-onset rheumatoid arthritis, gut enteropathies and autoimmune cytopenias. Whilst many effects of *STAT3* loss-of-function on immune cells have been described, the mechanisms behind autoimmunity and immunodeficiency in patients with *STAT3*-activating mutations remain unclear. Here, we present a detailed characterisation of T cell development and maturation in young and old mice on two different backgrounds with Crispr-engineered germline activating mutations in two domains of *STAT3*. We use mixed chimeras, flow cytometric analysis, T cell receptor deep-sequencing and high-throughput single-cell transcriptomics to reveal cell-extrinsic and -autonomous roles of *STAT3* activation in T cells in autoimmunity versus immune malignancy. To our knowledge, this is the first report of mice with *Stat3* germline activating mutations identical to those in autoimmunity or malignancy. We validate our key findings in humans with gain-of-function germline *STAT3* mutations and childhood-onset autoimmune disease.

**Keywords:** Ageing, animal models, autoimmunity, cytokines and mediators, immunodeficiency

## P-0809

**Report on lower anti-pneumococcus IgG1 levels in men, especially over the age of fifty**

Sanja Knežević<sup>1</sup>, Dejana Kosanović<sup>1</sup>, Irena Živković<sup>1</sup>, Vesna Ilić<sup>2</sup>, Luka Dragačević<sup>2</sup>, Ljiljana Hajduković<sup>3</sup>, **Rajna Minić<sup>1</sup>**

<sup>1</sup>*Institute of Virology, Vaccines and Sera, Torlak, Belgrade, Serbia*

<sup>2</sup>*Institute for Medical Research, Belgrade, Serbia*

<sup>3</sup>*Institute for Application of Nuclear Energy, Belgrade, Serbia*

*Streptococcus pneumoniae*, the pneumococcus is an important human pathogen. It possesses a capsule which has been thoroughly studied, since it is an important factor in virulence. In this work *S. pneumoniae* ATCC 6301, belonging to Serogroup 1, was used as a model organism to determine the levels of different IgG isotypes specific to this bacterium in different sex and age groups. For this purpose an in-house ELISA was used. Although IgG2 is a major antibacterial antibody subclass, acting against polysaccharide antigens, the level of pneumococcus-specific IgG2 did not differ from the level of IgG2 specific to several tested lactic acid bacteria (LAB). On the other hand pneumococcus specific IgG1 level was significantly higher to the level of LAB specific IgG1. This is most likely a consequence of previous encounters with pathogenic pneumococcal microorganism and a distinguishing characteristic of this encounter. By analyzing different sex and age groups we found significantly lower anti-pneumococcus IgG1 levels in men, implying lower protection against invasion with pneumococcus, which possibly translates to other encapsulated bacteria. The Covid-19 pandemic has identified males as being at increased risk of hospital admission and death and lower levels of anti-pneumococcus antibodies might be a contributing factor. Hence, we advocate the immunization with conjugate pneumococcal vaccines in male individuals, especially over the age of 50.

**Keywords:** Adaptive immunity, ageing, antibody

## P-0810

**A case of primary hemophagocytic syndrome seen in adult age**

**Kemal Fidan<sup>1</sup>**, Muzaffer Keklik<sup>1</sup>, Neslihan Mandacı Şanlı<sup>1</sup>, Gülşah Akyol<sup>1</sup>, Mustafa Baydar<sup>1</sup>, Serhat Çelik<sup>1</sup>, Zeynep Tuğba Güven<sup>1</sup>, Hatice Gözde Demir<sup>2</sup>, Ali Ünal<sup>1</sup>

<sup>1</sup>*Erciyes University Faculty of Medicine, Department of Hematology*

<sup>2</sup>*Erciyes University Faculty of Medicine, Department of Internal Medicine*

Hemophagocytic lymphohistiocytosis (HLH) is an immune disorder with high mortality due to uncontrolled activation of T lymphocytes and macrophages and excessive proliferation of inflammatory cytokines. A 37-year-old female patient diagnosed with pimer HLH is presented here. A 37-year-old female patient, was hospitalized with complaints of fever, weakness, and joint pain. Laboratory tests; Hemoglobine: 6.8 gr/dl, Wbc: 1.06x10<sup>3</sup>/uL, plt: 8x10<sup>3</sup>/uL neutrophil: 0.73x10<sup>3</sup>/uL, lymphocyte: 0.18x10<sup>3</sup>/uL, fibrinogen: 160.18 mg/dl, ALT: 118 u/L, LDH: 302 u/L, total bilirubin: 1.72 mg /dl, albumine: 2.76 g/dl, BUN: 15 mg/dl, creatinine: 0.73 mg/dl, CRP: 32.81 mg/L, triglyceride: 405 mg/dl, ferritin: 2820 mg/dl. On abdominal USG, the liver was 167mm, spleen 200mm. The bone marrow pathology result was consistent with hemophagocytosis. The patient's NK cytotoxicity was low. As a result of the genetic whole exon sequencing performed upon the presence of a family history; PRF1 / NM-001083116 / EXZON 3, C.560C> G p (Pro187Arg) came as homozygous. HLH 2004 protocol was started with the diagnosis of familial hemophagocytic syndrome. Allogeneic bone marrow transplant was planned for the patient. Pulse steroid was initiated and plasma exchange was performed due to diffuse alveolar hemorrhage in thoracic tomography performed upon the development of dyspnea, tachypnea and tachycardia at the 7th week of the treatment. The patient died at the 8th week of the treatment. In adult patients, primary hemophagocytic syndrome should be considered in differential diagnosis, treatment should be initiated after diagnosis and bone marrow transplantation should be performed as soon as possible.

**Keywords:** Autoimmunity, cytokines and mediators, granulocytes, immunodeficiency, lymphoid organs, macrophage

## P-0812

**What about the cytokines for the etiology of idiopathic granulomatous mastitis?**

Coskun Cakir<sup>1</sup>, Ali Emre Nayci<sup>1</sup>, Ekrem Ferlengez<sup>1</sup>, Mert Guler<sup>1</sup>, **Ufuk Oguz Idiz<sup>2</sup>**

<sup>1</sup>*Department of General Surgery, Istanbul Training and Research Hospital, Istanbul, Turkey*

<sup>2</sup>*Department of Immunology, Istanbul University DETA, Istanbul, Turkey*

Few things are known about the etiology of Idiopathic Granulomatous Mastitis. It was associated with autoimmunity, but no significant evidence was determined. In this study, we aimed to investigate the roles of cytokines in the etiopathogenesis of Idiopathic Granulomatous Mastitis. Idiopathic Granulomatous Mastitis patients in active or remission who admitted to the breast diseases outpatient clinic and healthy volunteers were included prospectively in the present study. The IL-1 $\beta$ , IFN- $\alpha$ 2, IFN- $\gamma$ , TNF- $\alpha$ , MCP-1, IL-6, IL-8, IL-10, IL-12p (p70), IL-17A, IL-18, IL-23 and IL-33 values were measured with Flow Cytometry. The blood samples were taken before the treatment in active Idiopathic Granulomatous Mastitis group. The ages, physical examination findings, menopausal conditions, smoking conditions, and treatment methods were also evaluated. A total of 32 patients, including 19 active and 13 remission patients, and 18 controls, were included in the present study, which made a total of 50 people. The mean age was 37.18 $\pm$ 7.15. The IL-1 $\beta$ , TNF- $\alpha$ , IL-10 and IL-18 values were lower in patients with Idiopathic Granulomatous Mastitis than the control group. Granulomatous Mastitis patients smoked more than control. When the active patients, remission patients, and control group were evaluated together, no significant differences were detected. In our study, the low rate of cytokines which are important for autoimmune and granulomatous reactions, especially cytokines associated with Th1 and Th17, in patients with idiopathic granulomatous mastitis suggests that these cytokines may not play a role in the etiopathogenesis, and that different mechanisms may be effective.

**Keywords:** Adaptive immunity, autoimmunity, chronic inflammation and fibrosis, cytokines and mediators